Adrenal Insufficiency
Nephrology·MeSH: Adrenal Insufficiency
Prevalence
30.0 / 100K
3 drugs in development·2 companies·0 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| efmody | NEUROCRINE BIOSCIENCES INC (NBIX) |
Preclinical(1)
| Drug | Company |
|---|---|
| et-800 | Eton Pharmaceuticals, Inc. (ETON) |
BLA Filed(1)
| Drug | Company |
|---|---|
| et-400 | Eton Pharmaceuticals, Inc. (ETON) |
Compare drugs
Frequently asked questions
How many drugs are in development for Adrenal Insufficiency?
BioSniper tracks 3 drugs in development for Adrenal Insufficiency across 2 companies.
What is the prevalence of Adrenal Insufficiency?
The estimated prevalence of Adrenal Insufficiency is approximately 30.0 per 100,000 population.
Deep-dive into Adrenal Insufficiency
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis